XML 35 R24.htm IDEA: XBRL DOCUMENT
v3.25.3

REVENUES (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Revenue from Contract with Customer [Abstract] |
Summary of Total Revenues | The following table summarizes our Total revenues:
|  | Three Months Ended September 30, 2025 |  | Three Months Ended September 30, 2024
(in millions) |  | U.S. |  | Europe |  | Rest of World |  | Total |  | U.S. |  | Europe |  | Rest of World |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biktarvy |  | $ | 2,940 |  |  | $ | 427 |  |  | $ | 320 |  |  | $ | 3,686 |  |  | $ | 2,826 |  |  | $ | 375 |  |  | $ | 272 |  |  | $ | 3,472 |
Descovy |  | 652 |  |  | 23 |  |  | 25 |  |  | 701 |  |  | 534 |  |  | 24 |  |  | 28 |  |  | 586 |
Genvoya |  | 323 |  |  | 34 |  |  | 19 |  |  | 377 |  |  | 384 |  |  | 44 |  |  | 21 |  |  | 449 |
Odefsey |  | 206 |  |  | 61 |  |  | 10 |  |  | 277 |  |  | 248 |  |  | 69 |  |  | 9 |  |  | 326 |
Symtuza - Revenue share(1) |  | 95 |  |  | 26 |  |  | 3 |  |  | 124 |  |  | 103 |  |  | 33 |  |  | 3 |  |  | 139 |
Other HIV(2) |  | 82 |  |  | 22 |  |  | 9 |  |  | 112 |  |  | 65 |  |  | 26 |  |  | 9 |  |  | 100 |
Total HIV |  | 4,299 |  |  | 592 |  |  | 386 |  |  | 5,277 |  |  | 4,161 |  |  | 570 |  |  | 342 |  |  | 5,073 |
Liver Disease |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sofosbuvir/Velpatasvir(3) |  | 146 |  |  | 65 |  |  | 97 |  |  | 309 |  |  | 222 |  |  | 67 |  |  | 96 |  |  | 385 |
Vemlidy |  | 136 |  |  | 12 |  |  | 132 |  |  | 280 |  |  | 126 |  |  | 11 |  |  | 95 |  |  | 232 |
Other Liver Disease(4) |  | 132 |  |  | 81 |  |  | 17 |  |  | 231 |  |  | 45 |  |  | 54 |  |  | 17 |  |  | 116 |
Total Liver Disease |  | 414 |  |  | 158 |  |  | 247 |  |  | 819 |  |  | 393 |  |  | 132 |  |  | 207 |  |  | 733 |
Veklury |  | 140 |  |  | 43 |  |  | 93 |  |  | 277 |  |  | 393 |  |  | 81 |  |  | 219 |  |  | 692 |
Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cell Therapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tecartus |  | 40 |  |  | 35 |  |  | 8 |  |  | 83 |  |  | 63 |  |  | 29 |  |  | 6 |  |  | 98 |
Yescarta |  | 123 |  |  | 151 |  |  | 75 |  |  | 349 |  |  | 145 |  |  | 182 |  |  | 60 |  |  | 387 |
Total Cell Therapy |  | 163 |  |  | 186 |  |  | 83 |  |  | 432 |  |  | 208 |  |  | 211 |  |  | 66 |  |  | 485 |
Trodelvy |  | 221 |  |  | 89 |  |  | 47 |  |  | 357 |  |  | 226 |  |  | 80 |  |  | 26 |  |  | 332 |
Total Oncology |  | 384 |  |  | 275 |  |  | 129 |  |  | 788 |  |  | 433 |  |  | 291 |  |  | 92 |  |  | 816 |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AmBisome |  | 2 |  |  | 69 |  |  | 52 |  |  | 123 |  |  | 6 |  |  | 71 |  |  | 52 |  |  | 130 |
Other(5) |  | 34 |  |  | 7 |  |  | 20 |  |  | 61 |  |  | 47 |  |  | 8 |  |  | 16 |  |  | 71 |
Total Other |  | 36 |  |  | 76 |  |  | 72 |  |  | 184 |  |  | 53 |  |  | 80 |  |  | 68 |  |  | 201 |
Total product sales |  | 5,274 |  |  | 1,144 |  |  | 928 |  |  | 7,345 |  |  | 5,433 |  |  | 1,154 |  |  | 928 |  |  | 7,515 |
Royalty, contract and other revenues |  | 7 |  |  | 411 |  |  | 5 |  |  | 424 |  |  | 17 |  |  | 13 |  |  | 1 |  |  | 30 |
Total revenues |  | $ | 5,281 |  |  | $ | 1,555 |  |  | $ | 933 |  |  | $ | 7,769 |  |  | $ | 5,450 |  |  | $ | 1,167 |  |  | $ | 929 |  |  | $ | 7,545 |
|  | Nine Months Ended September 30, 2025 |  | Nine Months Ended September 30, 2024
(in millions) |  | U.S. |  | Europe |  | Rest of World |  | Total |  | U.S. |  | Europe |  | Rest of World |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biktarvy |  | $ | 8,212 |  |  | $ | 1,231 |  |  | $ | 922 |  |  | $ | 10,366 |  |  | $ | 7,726 |  |  | $ | 1,110 |  |  | $ | 814 |  |  | $ | 9,649 |
Descovy |  | 1,791 |  |  | 67 |  |  | 81 |  |  | 1,939 |  |  | 1,339 |  |  | 75 |  |  | 82 |  |  | 1,496 |
Genvoya |  | 950 |  |  | 114 |  |  | 54 |  |  | 1,118 |  |  | 1,088 |  |  | 138 |  |  | 66 |  |  | 1,292 |
Odefsey |  | 642 |  |  | 184 |  |  | 30 |  |  | 857 |  |  | 705 |  |  | 217 |  |  | 30 |  |  | 952 |
Symtuza - Revenue share(1) |  | 265 |  |  | 88 |  |  | 9 |  |  | 362 |  |  | 338 |  |  | 101 |  |  | 9 |  |  | 448 |
Other HIV(2) |  | 198 |  |  | 85 |  |  | 28 |  |  | 310 |  |  | 190 |  |  | 96 |  |  | 36 |  |  | 322 |
Total HIV |  | 12,059 |  |  | 1,769 |  |  | 1,124 |  |  | 14,952 |  |  | 11,386 |  |  | 1,737 |  |  | 1,038 |  |  | 14,160 |
Liver Disease |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sofosbuvir/Velpatasvir(3) |  | 497 |  |  | 227 |  |  | 273 |  |  | 996 |  |  | 737 |  |  | 230 |  |  | 299 |  |  | 1,266 |
Vemlidy |  | 358 |  |  | 36 |  |  | 389 |  |  | 783 |  |  | 338 |  |  | 33 |  |  | 328 |  |  | 699 |
Other Liver Disease(4) |  | 307 |  |  | 233 |  |  | 53 |  |  | 593 |  |  | 134 |  |  | 148 |  |  | 55 |  |  | 337 |
Total Liver Disease |  | 1,162 |  |  | 496 |  |  | 714 |  |  | 2,372 |  |  | 1,210 |  |  | 411 |  |  | 682 |  |  | 2,302 |
Veklury |  | 390 |  |  | 84 |  |  | 225 |  |  | 700 |  |  | 784 |  |  | 204 |  |  | 473 |  |  | 1,461 |
Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cell Therapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tecartus |  | 122 |  |  | 107 |  |  | 25 |  |  | 254 |  |  | 181 |  |  | 102 |  |  | 22 |  |  | 305 |
Yescarta |  | 444 |  |  | 455 |  |  | 228 |  |  | 1,127 |  |  | 502 |  |  | 509 |  |  | 170 |  |  | 1,181 |
Total Cell Therapy |  | 566 |  |  | 562 |  |  | 253 |  |  | 1,381 |  |  | 683 |  |  | 611 |  |  | 192 |  |  | 1,485 |
Trodelvy |  | 626 |  |  | 259 |  |  | 128 |  |  | 1,013 |  |  | 655 |  |  | 217 |  |  | 88 |  |  | 960 |
Total Oncology |  | 1,192 |  |  | 821 |  |  | 381 |  |  | 2,395 |  |  | 1,338 |  |  | 828 |  |  | 280 |  |  | 2,446 |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AmBisome |  | 15 |  |  | 201 |  |  | 175 |  |  | 391 |  |  | 37 |  |  | 210 |  |  | 176 |  |  | 424 |
Other(5) |  | 125 |  |  | 23 |  |  | 55 |  |  | 204 |  |  | 203 |  |  | 26 |  |  | 52 |  |  | 281 |
Total Other |  | 140 |  |  | 225 |  |  | 230 |  |  | 594 |  |  | 241 |  |  | 236 |  |  | 228 |  |  | 705 |
Total product sales |  | 14,943 |  |  | 3,395 |  |  | 2,674 |  |  | 21,013 |  |  | 14,958 |  |  | 3,416 |  |  | 2,700 |  |  | 21,074 |
Royalty, contract and other revenues |  | 57 |  |  | 433 |  |  | 16 |  |  | 505 |  |  | 66 |  |  | 43 |  |  | 2 |  |  | 111 |
Total revenues |  | $ | 15,000 |  |  | $ | 3,828 |  |  | $ | 2,690 |  |  | $ | 21,518 |  |  | $ | 15,024 |  |  | $ | 3,459 |  |  | $ | 2,703 |  |  | $ | 21,185 |
_______________________________ (1) Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen Ireland”). (2) Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada, Tybost and Yeztugo/Yeytuo. (3) Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”). (4) Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi/Lyvdelzi, Sovaldi, Viread and Vosevi. (5) Includes Cayston, Jyseleca, Letairis and Zydelig.
Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods | The following table summarizes revenues recognized from performance obligations satisfied in prior years:
|  | Three Months Ended |  | Nine Months Ended
|  | September 30, |  | September 30,
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Revenue share with Janssen Ireland and royalties for licenses of intellectual property |  | $ | 148 |  |  | $ | 173 |  |  | $ | 458 |  |  | $ | 545 |
Changes in estimates(1) |  | $ | 497 |  |  | $ | 146 |  |  | $ | 837 |  |  | $ | 388 |
_______________________________ (1) Changes in estimates increased during the three and nine months ended September 30, 2025 primarily due to recognition of $400 million of previously constrained revenues from the sale of certain intellectual property.
Summary of Contract Balances | The following table summarizes our contract balances:
(in millions) |  | September 30, 2025 |  | December 31, 2024
Contract assets(1) |  | $ | 695 |  |  | $ | 277 |
Contract liabilities(2) |  | $ | 56 |  |  | $ | 58 |
_______________________________ (1) The increase in contract assets during the nine months ended September 30, 2025 primarily related to recognition of $400 million of previously constrained revenues from the sale of certain intellectual property. (2) Future revenues recognized from contract liabilities are not expected to be material in any one year.

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of expected timing for satisfying remaining performance obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration